Andere Sprachen Elevai Labs Inc.

Aktien

A3EB4B

US28622K1043

ELAB

Markt geschlossen - Nasdaq Andere Börsenplätze 21:55:56 23.05.2024			% 5 Tage	% 1. Jan.
0.6599 ^USD	-0.77%		+1.51%	-63.90%

02.05.	Elevai Biosciences Inc. hebt präklinische Daten hervor, die das Potenzial des einlizenzierten Wirkstoffs EL-22 für die Behandlung von Fettleibigkeit belegen	CI
01.05.	Elevai Labs expandiert mit der Gründung der Tochtergesellschaften Elevai Biosciences und Elevai Skincare	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference	22.05.
Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	19.05.
Elevai Labs Inc. Reports First Quarter 2024 Financial Results	15.05.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity	02.05.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity	02.05.
Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity	02.05.
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare	01.05.
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries	01.05.
Elevai Labs Inc. Announces Executive Changes	01.05.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments	01.05.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments	01.05.
Elevai Labs Enters into Exclusive Licensing Agreement with MOA Life Plus Co., Ltd to Develop and Commercialize Two Novel Assets for the Treatment of Obesity and Muscle Loss Prevention	01.05.
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments	29.04.
Elevai Labs Signs Exclusive Distribution Deal for Taiwan	22.04.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months	22.04.
Elevai Labs, Inc. Enters the Taiwan Market with Signing of 5Th International Distribution Agreement in 14 Months	22.04.
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results	29.03.
Elevai Labs, Inc. Launches E-Commerce Portal	18.03.
Elevai Labs, Inc. Announces Board Changes	07.03.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office	24.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Elevai Labs Inc.

Aktien

A3EB4B

US28622K1043

ELAB

Andere Sprachen

Filter